US stock futures dip as Nvidia earnings spark little cheer
Investing.com -- iBio Inc (NASDAQ:IBIO) stock surged 50% after the company announced preclinical data showing its engineered amylin receptor agonist antibody reduced acute food intake by 60% in a mouse model of obesity.
The AI-driven biotech firm reported that its collaboration with AstralBio has yielded multiple novel engineered antibody agonists targeting the amylin receptor, a heterodimeric G protein-coupled receptor. The company’s approach focuses on selective activation of the amylin receptor rather than dual agonism of amylin and calcitonin receptors, which they believe could match or exceed DACRA efficacy with improved tolerability.
iBio’s technology allows precise targeting of the amylin receptor and its subtypes, positioning the company to potentially compete in the rapidly growing obesity treatment market. The amylin hormone naturally regulates satiety and delays gastric emptying, making its receptor a promising therapeutic target for obesity and cardiometabolic diseases.
The company noted that other amylin analogs in clinical development have achieved body weight reductions of up to 22.7% when used with semaglutide and 11.8% as monotherapy. iBio’s approach targets different signaling pathways, potentially enhancing weight-loss efficacy when combined with GLP-1 receptor agonists or serving as an alternative for patients who don’t respond well to GLP-1-based treatments.
iBio leverages its proprietary Drug Discovery (NASDAQ:WBD) Platform and advanced AI to develop antibodies with high selectivity and potency, aiming to discover molecules that could become best-in-class therapeutics for weight management with optimal tolerability and lean mass preservation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.